annual CFO:
-$414.19M+$60.62M(+12.77%)Summary
- As of today (July 6, 2025), RARE annual cash flow from operations is -$414.19 million, with the most recent change of +$60.62 million (+12.77%) on December 31, 2024.
- During the last 3 years, RARE annual CFO has fallen by -$75.49 million (-22.29%).
- RARE annual CFO is now -7010.52% below its all-time high of -$5.83 million, reached on December 31, 2011.
Performance
RARE Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$166.47M-$86.97M(-109.39%)Summary
- As of today (July 6, 2025), RARE quarterly cash flow from operations is -$166.47 million, with the most recent change of -$86.97 million (-109.39%) on March 31, 2025.
- Over the past year, RARE quarterly CFO has increased by +$24.25 million (+12.72%).
- RARE quarterly CFO is now -290.58% below its all-time high of $87.35 million, reached on June 30, 2020.
Performance
RARE quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$389.94M+$24.25M(+5.86%)Summary
- As of today (July 6, 2025), RARE TTM cash flow from operations is -$389.94 million, with the most recent change of +$24.25 million (+5.86%) on March 31, 2025.
- Over the past year, RARE TTM CFO has increased by +$118.73 million (+23.34%).
- RARE TTM CFO is now -6096.35% below its all-time high of -$6.29 million, reached on March 31, 2013.
Performance
RARE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RARE Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.8% | +12.7% | +23.3% |
| 3 y3 years | -22.3% | -41.7% | -31.4% |
| 5 y5 years | -19.9% | -75.0% | -131.6% |
RARE Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.3% | +12.8% | -148.5% | +12.7% | -26.3% | +23.3% |
| 5 y | 5-year | -213.3% | +12.8% | -290.6% | +12.7% | -194.9% | +23.3% |
| alltime | all time | -7010.5% | +12.8% | -290.6% | +12.7% | -6096.4% | +23.3% |
RARE Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$166.47M(+109.4%) | -$389.94M(-5.9%) |
| Dec 2024 | -$414.19M(-12.8%) | -$79.50M(+18.7%) | -$414.19M(-1.1%) |
| Sep 2024 | - | -$67.00M(-13.0%) | -$418.59M(-10.8%) |
| Jun 2024 | - | -$76.96M(-59.6%) | -$469.47M(-7.7%) |
| Mar 2024 | - | -$190.73M(+127.3%) | -$508.67M(+7.1%) |
| Dec 2023 | -$474.81M(+24.8%) | -$83.90M(-28.8%) | -$474.81M(-1.3%) |
| Sep 2023 | - | -$117.87M(+1.5%) | -$481.24M(+4.9%) |
| Jun 2023 | - | -$116.16M(-25.9%) | -$458.71M(+9.3%) |
| Mar 2023 | - | -$156.87M(+73.6%) | -$419.81M(+10.3%) |
| Dec 2022 | -$380.46M(+12.3%) | -$90.34M(-5.2%) | -$380.46M(+10.5%) |
| Sep 2022 | - | -$95.34M(+23.4%) | -$344.47M(+11.6%) |
| Jun 2022 | - | -$77.26M(-34.3%) | -$308.77M(+4.0%) |
| Mar 2022 | - | -$117.52M(+116.3%) | -$296.87M(-12.3%) |
| Dec 2021 | -$338.69M(+156.2%) | -$54.34M(-8.9%) | -$338.69M(-2.3%) |
| Sep 2021 | - | -$59.65M(-8.7%) | -$346.80M(-0.7%) |
| Jun 2021 | - | -$65.36M(-59.0%) | -$349.12M(+77.7%) |
| Mar 2021 | - | -$159.35M(+155.1%) | -$196.41M(+48.6%) |
| Dec 2020 | -$132.22M(-61.7%) | -$62.45M(+0.8%) | -$132.22M(-6.8%) |
| Sep 2020 | - | -$61.97M(-170.9%) | -$141.81M(-15.8%) |
| Jun 2020 | - | $87.35M(-191.8%) | -$168.35M(-51.2%) |
| Mar 2020 | - | -$95.15M(+32.1%) | -$344.76M(-0.2%) |
| Dec 2019 | -$345.38M(+18.9%) | -$72.04M(-18.6%) | -$345.38M(+4.9%) |
| Sep 2019 | - | -$88.51M(-0.6%) | -$329.20M(+6.2%) |
| Jun 2019 | - | -$89.06M(-7.0%) | -$309.85M(+4.4%) |
| Mar 2019 | - | -$95.78M(+71.5%) | -$296.86M(+2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$290.57M(+14.5%) | -$55.85M(-19.2%) | -$290.57M(-8.2%) |
| Sep 2018 | - | -$69.16M(-9.1%) | -$316.54M(+2.3%) |
| Jun 2018 | - | -$76.08M(-15.0%) | -$309.37M(+9.7%) |
| Mar 2018 | - | -$89.48M(+9.4%) | -$282.12M(+11.1%) |
| Dec 2017 | -$253.84M(+57.7%) | -$81.82M(+32.0%) | -$253.84M(+15.5%) |
| Sep 2017 | - | -$61.99M(+27.0%) | -$219.70M(+17.8%) |
| Jun 2017 | - | -$48.82M(-20.2%) | -$186.45M(+5.2%) |
| Mar 2017 | - | -$61.20M(+28.4%) | -$177.28M(+10.1%) |
| Dec 2016 | -$160.97M(+51.9%) | -$47.68M(+65.9%) | -$160.97M(+4.7%) |
| Sep 2016 | - | -$28.75M(-27.5%) | -$153.74M(-1.2%) |
| Jun 2016 | - | -$39.66M(-11.7%) | -$155.59M(+16.8%) |
| Mar 2016 | - | -$44.90M(+11.0%) | -$133.21M(+25.7%) |
| Dec 2015 | -$105.98M(+137.4%) | -$40.44M(+32.2%) | -$105.98M(+35.9%) |
| Sep 2015 | - | -$30.60M(+77.2%) | -$77.99M(+33.5%) |
| Jun 2015 | - | -$17.27M(-2.2%) | -$58.42M(+13.1%) |
| Mar 2015 | - | -$17.66M(+41.8%) | -$51.67M(+15.8%) |
| Dec 2014 | -$44.63M(+43.1%) | -$12.45M(+12.9%) | -$44.63M(+6.4%) |
| Sep 2014 | - | -$11.03M(+4.8%) | -$41.95M(+11.4%) |
| Jun 2014 | - | -$10.53M(-0.9%) | -$37.67M(+6.0%) |
| Mar 2014 | - | -$10.62M(+8.7%) | -$35.53M(+13.9%) |
| Dec 2013 | -$31.20M(+149.5%) | -$9.77M(+44.8%) | -$31.20M(+45.6%) |
| Sep 2013 | - | -$6.75M(-19.6%) | -$21.43M(+46.0%) |
| Jun 2013 | - | -$8.39M(+33.3%) | -$14.68M(+133.3%) |
| Mar 2013 | - | -$6.29M | -$6.29M |
| Dec 2012 | -$12.50M(+114.7%) | - | - |
| Dec 2011 | -$5.83M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual cash flow from operations?
- What is the all time high annual CFO for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual CFO year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from operations?
- What is the all time high quarterly CFO for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly CFO year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM cash flow from operations?
- What is the all time high TTM CFO for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM CFO year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual cash flow from operations?
The current annual CFO of RARE is -$414.19M
What is the all time high annual CFO for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual cash flow from operations is -$5.83M
What is Ultragenyx Pharmaceutical Inc. annual CFO year-on-year change?
Over the past year, RARE annual cash flow from operations has changed by +$60.62M (+12.77%)
What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from operations?
The current quarterly CFO of RARE is -$166.47M
What is the all time high quarterly CFO for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly cash flow from operations is $87.35M
What is Ultragenyx Pharmaceutical Inc. quarterly CFO year-on-year change?
Over the past year, RARE quarterly cash flow from operations has changed by +$24.25M (+12.72%)
What is Ultragenyx Pharmaceutical Inc. TTM cash flow from operations?
The current TTM CFO of RARE is -$389.94M
What is the all time high TTM CFO for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM cash flow from operations is -$6.29M
What is Ultragenyx Pharmaceutical Inc. TTM CFO year-on-year change?
Over the past year, RARE TTM cash flow from operations has changed by +$118.73M (+23.34%)